

## FivePrime Therapeutics Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 01-Feb-2014

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drugs..... 12

[Return to Table of Contents](#)

# FivePrime Therapeutics Inc

## COMPANY OVERVIEW

Company Name	FivePrime Therapeutics Inc
Parent Company Name	FivePrime Therapeutics Inc
Website	<a href="http://www.fiveprime.com/">http://www.fiveprime.com/</a>
Country	US
Number of Drugs in Active Development	7
Number of Inactive Drugs	12
Number of Patents as Owner	43
Number of Patents as Third Party	1
Number of Deals	15
Key Indications	Cancer,Endometrioid carcinoma,Chronic obstructive pulmonary disease,Osteoarthritis,Stomach tumor,Asthma,Non-small-cell lung cancer,Autoimmune disease,Cachexia,Fibrosis,Idiopathic pulmonary fibrosis,Musculoskeletal disease,Sarcopenia,Unidentified indication
Key Target-based Actions	FGF2 receptor antagonist,CSF-1 antagonist,FGF1 receptor antagonist,Amphiregulin ligand modulator,Extracellular signal related kinase-1 stimulator,Extracellular signal related kinase-2 stimulator,IL antagonist,Insulin sensitizer,Interleukin 27 alpha ligand modulator,FGF1 receptor agonist
Key Technologies	Biological therapeutic,Parenteral formulation unspecified,Peptide,Protein recombinant,Antibody,Protein fusion,Monoclonal antibody humanized,Immunoglobulin-G,Antibody fragment,Infusion,Intravenous formulation,Small molecule therapeutic

## COMPANY PROFILE

### SUMMARY

FivePrime Therapeutics Inc was set up in 2002 by the founder of Chiron Corp to speed the discovery and development of first in-class protein and antibody drugs. The company has integrated multiple technologies into a discovery engine that enables systematic, high-throughput screening of whole sets of secreted proteins and receptors to address unmet medical needs in the areas of oncology and immunology.

### COMPANY LOCATION

In October 2010, the company relocated to a new drug discovery facility in South San Francisco, CA.

In December 2005, FivePrime relocated from South San Francisco, CA, to Mission Bay, San Francisco, CA.

### LICENSING AGREEMENTS

In May 2008, FivePrime entered into a collaborative research program with Pfizer to discover and develop novel antibody targets and therapeutic proteins in the fields of diabetes and cancer. The collaboration would use FivePrime's rapid protein discovery platform, which screens FivePrime's target libraries using cell-based assays and in vivo, high-throughput screening techniques. FivePrime would receive an upfront payment, equity investment and research funding for three years, while Pfizer was granted exclusive worldwide development and commercialization rights to any emerging compounds in return for future milestone and royalty payments.

In January 2007, Five Prime Therapeutics signed a worldwide collaborative research and license agreement with Centocor which would focus on novel therapeutics for osteoarthritis and pulmonary fibrosis. FivePrime would screen its comprehensive protein library against cell-based assays directed to osteoarthritis and fibrosis and Centocor would have exclusive rights to the proteins and targets identified. In February 2010, FivePrime received a milestone payment from Centocor for the selection of a therapeutic for the potential treatment of immunology-related indications.

In April 2006, FivePrime entered a \$75 million, 2-year research deal with Boehringer Ingelheim to discover rheumatoid arthritis drugs. FivePrime would receive an upfront fee, research support, milestones and royalties, while Boehringer gained exclusive global rights to develop and commercialize any products and targets discovered. The basis of the deal

[Return to Table of Contents](#)



was FivePrime's protein screening library of all human secreted proteins and their receptors.

In February 2006, Biosite granted FivePrime access to its Omniconal antibodies for use in therapeutic research programs. In return, Biosite would be able to use FivePrime's functional disease targets for the development of diagnostics.

By April 2004, FivePrime had established a strategic technology collaboration with Dnaform Inc, granting FivePrime the rights to use Dnaform's high-throughput cloning technologies for the creation of full length human cDNA libraries.

## EARLY R&D

In May 2008, researchers from the company published a paper describing the discovery of interleukin-34 (IL-34) and the identification of its receptor. IL-34 was found to be highly specific in increasing the viability of primary monocyte while having no activity against other cell types.

By April 2006, the company was researching FPT-025, a cytokine that expands monocytes and participates in early differentiation of dendritic cells. At that time, the agent's potential in oncology, inflammation and infectious disease was being looked at.

By April 2004, the company was in hit validation for immune regulation and type 2 diabetes, in high-throughput screening for lymphogenesis, and in target validation in oncology. Novel splice variants of genes implicated in immune modulation had been discovered, and FivePrime had identified novel functions for known genes in the regulation of mature T, B and monocytic cells. Its metabolic disorder studies were focussed on three areas: protein insulin mimetics, protein insulin sensitizers, and protein-based insulin resistance, and the company had identified protein factors that enhance glucose uptake and was validating these for activity in secondary in vitro assays and mouse obesity-driven diabetes models. In lymphogenesis, FivePrime was screening for factors that accelerate and enhance the reconstitution of lymphoid cells for the treatment of immunocompromised cancer patients after bone marrow transplant. In addition the company was pursuing both antibodies to these factors, and proteins that are natural inhibitors of lymphogenesis for treatment of autoimmune and chronic inflammatory diseases. Within its oncology program, the company was developing therapeutic antibodies targeting key members of growth factors and their receptors; FivePrime has used its Whole Set of secreted proteins and receptors to build a microarray (Pharmanome) that contains hundreds of probes for secreted factors, receptors and other druggable targets, and was validating several targets before testing in xenograft models.

## FINANCIAL

In September 2013, FivePrime priced its initial public offering of 4,800,000 shares of its common stock at \$13.00 each, for an aggregate offering of \$62.4 million. In addition, the company granted a 30-day option to the underwriters to purchase up to 720,000 additional shares of common stock to cover over-allotments. At that time, the offering was expected to close on September 23, 2013, and the company also announced that its common stock were to trade on NASDAQ under the symbol 'FPRX', from September 18, 2013. Later in September 2013, the company raised gross proceeds of \$62.4 million from the closed offering; later in the same month, the underwriters fully exercised their over-allotment option to purchase 720,000 additional common stock shares at \$13.00 per share, resulting in a total of 5.52 million shares sold for \$71.8 million in gross proceeds.

In February 2005, FivePrime completed a \$45 million private equity financing.

In September 2003, FivePrime raised \$12 million in a second private financing round.

[Return to Table of Contents](#)




## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart



[Return to Table of Contents](#)

## Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	2	5	7
Inflammatory disease	3	2	5
Respiratory disease	3	1	4
Gastrointestinal disease	1	3	4
Endocrine disease	1	2	3
Metabolic disorder	0	3	3
Musculoskeletal disease	2	1	3
Immune disorder	2	1	3
Nutritional disorder	1	1	2
Neurological disease	0	1	1
Genitourinary disease	1	0	1
Unidentified indication	1	0	1
Cardiovascular disease	0	1	1
Growth disorder	1	0	1
Infectious disease	0	1	1
Gynecology and obstetrics	1	0	1


[Return to Table of Contents](#)





## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Phase 1 Clinical	1
Discovery	5
No Development Reported	12

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Discovery/Design	2	0	1	0	3
Technology - Other Proprietary	0	0	4	0	4
Drug - Funding	1	0	0	0	1
Drug - Screening/Evaluation	1	0	0	0	2
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	3	0	1	0	4

[Return to Table of Contents](#)

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	0	3
Gynecology and obstetrics	0	2
Genitourinary disease	0	2
Endocrine disease	0	2
Inflammatory disease	1	1
Immune disorder	1	1
Musculoskeletal disease	1	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	0	2
Phase 1	1	2

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	17	0	17
Endocrine disease	20	0	20
Gastrointestinal disease	22	0	22
Genitourinary disease	11	0	11
Growth disorder	1	0	1
Hematological disease	6	0	6
Degeneration	4	0	4
Andrology	5	0	5

[Return to Table of Contents](#)



Immune disorder	25	0	25
Musculoskeletal disease	14	0	14
Neoplasm	30	1	31
Ocular disease	2	0	2
Genetic disorder	5	0	5
Metabolic disorder	12	0	12
Neurological disease	17	0	17
Nutritional disorder	3	1	4
Respiratory disease	13	0	13
Infectious disease	11	0	11
Injury	1	0	1
Inflammatory disease	22	0	22
Otorhinolaryngological disease	1	0	1
Gynecology and obstetrics	12	0	12
Dermatological disease	16	0	16
Surgical procedure	4	0	4

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### FP-1039

<b>Drug Name</b>	FP-1039
<b>Key Synonyms</b>	
<b>Originator Company</b>	FivePrime Therapeutics Inc
<b>Active Companies</b>	Human Genome Sciences Inc, FivePrime Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Non-small-cell lung cancer, Cancer, Endometrioid carcinoma
<b>Target-based Actions</b>	FGF1 receptor antagonist
<b>Other Actions</b>	Angiogenesis inhibitor, Anticancer protein kinase inhibitor
<b>Technologies</b>	Antibody fragment, Immunoglobulin-G, Intravenous formulation, Infusion, Biological therapeutic, Protein fusion
<b>Last Change Date</b>	10-Jan-2014

### FPA-008

<b>Drug Name</b>	FPA-008
<b>Key Synonyms</b>	
<b>Originator Company</b>	FivePrime Therapeutics Inc
<b>Active Companies</b>	FivePrime Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Fibrosis, Autoimmune disease
<b>Target-based Actions</b>	CSF-1 antagonist
<b>Other Actions</b>	Anti-inflammatory
<b>Technologies</b>	Monoclonal antibody humanized, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	13-Nov-2013

[Return to Table of Contents](#)

## FPA-126

<b>Drug Name</b>	FPA-126
<b>Key Synonyms</b>	
<b>Originator Company</b>	FivePrime Therapeutics Inc
<b>Active Companies</b>	GlaxoSmithKline plc, FivePrime Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Asthma, Chronic obstructive pulmonary disease
<b>Target-based Actions</b>	Interleukin 27 alpha ligand modulator
<b>Other Actions</b>	Respiratory system agent, Anti-inflammatory
<b>Technologies</b>	Antibody, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant
<b>Last Change Date</b>	28-Feb-2013

## therapeutic peptide program (osteoarthritis/pulmonary fibrosis), FivePrime/ Janssen Biotech

<b>Drug Name</b>	therapeutic peptide program (osteoarthritis/pulmonary fibrosis), FivePrime/ Janssen Biotech
<b>Key Synonyms</b>	
<b>Originator Company</b>	FivePrime Therapeutics Inc
<b>Active Companies</b>	FivePrime Therapeutics Inc, Janssen Biotech Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Idiopathic pulmonary fibrosis, Osteoarthritis
<b>Target-based Actions</b>	
<b>Other Actions</b>	Fibrosuppressant, Respiratory system agent, Anti-inflammatory
<b>Technologies</b>	Biological therapeutic, Parenteral formulation unspecified, Peptide
<b>Last Change Date</b>	28-Feb-2013

[Return to Table of Contents](#)

## secreted/transmembrane receptor proteins (musculoskeletal disorders), GSK/ FivePrime

<b>Drug Name</b>	secreted/transmembrane receptor proteins (musculoskeletal disorders), GSK/ FivePrime
<b>Key Synonyms</b>	
<b>Originator Company</b>	FivePrime Therapeutics Inc
<b>Active Companies</b>	GlaxoSmithKline plc, FivePrime Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Sarcopenia, Musculoskeletal disease, Cachexia
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target, Musculoskeletal system modulator
<b>Technologies</b>	Biological therapeutic, Parenteral formulation unspecified, Protein recombinant
<b>Last Change Date</b>	28-Feb-2013

## FPA-144

<b>Drug Name</b>	FPA-144
<b>Key Synonyms</b>	
<b>Originator Company</b>	FivePrime Therapeutics Inc
<b>Active Companies</b>	FivePrime Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Stomach tumor
<b>Target-based Actions</b>	FGF2 receptor antagonist
<b>Other Actions</b>	Anticancer protein kinase inhibitor, Anticancer monoclonal antibody
<b>Technologies</b>	Monoclonal antibody humanized, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	18-Sep-2013

[Return to Table of Contents](#)

### therapeutic antibody program, Dyax/FivePrime Therapeutics

<b>Drug Name</b>	therapeutic antibody program, Dyax/FivePrime Therapeutics
<b>Key Synonyms</b>	
<b>Originator Company</b>	FivePrime Therapeutics Inc
<b>Active Companies</b>	FivePrime Therapeutics Inc, Dyax Corp
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Unidentified indication
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target
<b>Technologies</b>	Antibody, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	07-Nov-2012

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)